(Q38101891)

28 August 2017

title

Insulin degludec and insulin degludec/insulin aspart: a review of their use in the management of diabetes mellitus (English)

1 reference

28 August 2017

1 reference

1

Gillian M Keating

1 reference

28 August 2017

publication date

1 May 2013

1 reference

28 August 2017

1 reference

28 August 2017

volume

73

1 reference

28 August 2017

issue

6

1 reference

28 August 2017

page(s)

575-593

1 reference

https://scigraph.springernature.com/pub.10.1007/s40265-013-0051-1

28 August 2017

exact match

0 references

cites work

Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Card

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0051-1

Standards of medical care in diabetes--2013

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0051-1

Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0051-1

How pharmacokinetic and pharmacodynamic principles pave the way for optimal basal insulin therapy in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0051-1

Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0051-1

Insulin Degludec, The New Generation Basal Insulin or Just another Basal Insulin?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0051-1

Ligand-controlled assembly of hexamers, dihexamers, and linear multihexamer structures by the engineered acylated insulin degludec

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0051-1

Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0051-1

Can a new ultra-long-acting insulin analogue improve patient care? Investigating the potential role of insulin degludec

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0051-1

Insulin degludec/insulin aspart administered once daily at any meal, with insulin aspart at other meals versus a standard basal-bolus regimen in patients with type 1 diabetes: a 26-week, phase 3, randomized, open-label, treat-to-target trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0051-1

Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0051-1

Insulin aspart: a review of its use in the management of type 1 or 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0051-1

Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0051-1

Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0051-1

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority tria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0051-1

Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0051-1

Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0051-1

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority tria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0051-1

The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in i

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0051-1

Insulin degludec improves health-related quality of life (SF-36® ) compared with insulin glargine in people with Type 2 diabetes starting on basal insulin: a meta-analysis of phase 3a trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0051-1

A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0051-1

Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0051-1

Long-term instability of fasting plasma glucose, a novel predictor of cardiovascular mortality in elderly patients with non-insulin-dependent diabetes mellitus: the Verona Diabetes Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0051-1

Efficacy and safety of ultra-long-acting insulin degludec

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0051-1

Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0051-1

Insulin detemir: a review of its use in the management of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0051-1

Diabetes and cancer: a consensus report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0051-1

A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0051-1

Basal insulin and cardiovascular and other outcomes in dysglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0051-1

Insulin degludec as an ultralong-acting basal insulin once a day: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0051-1

Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes

21 January 2018

1 reference

12 December 2020

Twice-daily compared with once-daily insulin glargine in people with Type 1 diabetes using meal-time insulin aspart

1 reference

12 December 2020

No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: a meta-analysis

1 reference

12 December 2020

Insulin degludec: a new ultra-longacting insulin

1 reference

12 December 2020

Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial.

1 reference

12 December 2020

10.1007/S40265-013-0051-1

Identifiers

DOI

1 reference

Dimensions Publication ID

28 August 2017

1036927709

0 references

1 reference